Navigation Links
Statins don't prove useful for general pediatric lupus population
Date:11/7/2010

ATLANTA, GA Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date.

Lupus is an autoimmune disease that causes widespread inflammation and organ damage. Children with lupus show early signs of atherosclerosis -- the fatty tissue buildup that is the precursor to clogged arteries. Previous research also indicates risk for heart attack and stroke in premenopausal women with lupus is 50 times greater than women the same age without the disease.

"As treatments for lupus improve and kids live longer, they are more likely to develop significant heart disease," says Laura Schanberg, MD, a professor of pediatrics at Duke University Medical Center who presented the findings at the American College of Rheumatology meeting in Atlanta. "We wanted to find a way to lower their risk."

Statins were the obvious choice for investigation since they have proven effective at decreasing heart disease incidence in many adult populations. "We thought every child with lupus should routinely be put on statins," Schanberg says. "This study proves that's not the case.

"The statins had positive effects on CRP and lipid levels, and they appear to be safe and well tolerated," says Schanberg, "But their effect on atherosclerosis was not significant enough to warrant routine use."

Schanberg, of the Duke Clinical Research Institute, and Stanford University professor Christy Sandborg, MD, were the co-principal investigators of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial. It randomized 221 participants with pediatric lupus (ages 10 to 21) from 21 sites within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) to two groups. One group received atorvastatin (Lipitor), the other received placebo for 36 months.

The researchers set out to determine if the use of statins resulted in a significant clinical difference that outweighed any potential risks. They used ultrasound techniques to detect thickening of the arterial wall of carotid arteries. They also studied blood lipid levels, inflammation markers including C-reactive protein (CRP), and lupus disease activity measures.

"There are rare long-term risks associated with statins that outweigh the risks of using them routinely without proof of clinically significant benefit," Schanberg says.

Further analysis is needed to determine whether sub groups of the study participants might derive more benefit from statin therapy.

"We're not saying statins should never be used in kids with lupus," she says. "Rather, we showed that statins should not be routinely prescribed to children with lupus. A lot more information has to go into the decision, and further investigation will help us arrive at a more definitive answer."


'/>"/>

Contact: Debbe Geiger
Debbe.Geiger@duke.edu
919-660-9461
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Aspirin, Statins May Reduce Problems After Heart Surgery
2. Statins May Guard Against Rheumatoid Arthritis
3. Study Suggests Statins Could Help Some With Normal Cholesterol
4. Statins, Painkillers May Upset PSA Test Results
5. Some on Statins May Not Need Boost in Good Cholesterol
6. Statins May Not Be as Helpful for Those Without Heart Disease
7. Statins May Lower Rates of Prostate Cancer Recurrence
8. Statins associated with lower cancer recurrence following prostatectomy
9. MSU team studies connection between statins, tendon ruptures
10. Too Many Stroke Patients Go Without Statins
11. Some statins have unintended effects and warrant closer monitoring, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing aids ... doesn’t have the stigma it had when great-grandpa wore his hearing aids years ago,” ... a NALA North American Speaker Series (NASS) segment. “He probably wore an ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in ... a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced ... benefits of a moisturizer with the power of an anti-aging concentrate. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: